ISTO To Present At NY Stem Cell Summit '14 - Siouxland News - KMEG 14 and FOX 44

ISTO To Present At NY Stem Cell Summit '14

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ISTO Technologies, Inc.

ST. LOUIS, Feb. 12, 2014 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held regenerative medicine company, announced today that Mitchell Seyedin, Ph.D., the Company's Executive Chairman, will present at the New York Stem Cell Summit 2014.

  • Date: Tuesday, February 18, 2014,
  • Venue: The Convene, Downtown, New York, New York
  • Session Time: 11:55 AM EST
  • Session Topic: Practical Methods for Combining Cells and Tissue Engineering

About ISTO Technologies, Inc. 

ISTO is a privately-held a regenerative medicine company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications.  ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.  The Company's proprietary cell-based platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue.   In addition to cell-based cartilage products in late stage clinical development, ISTO manufactures and markets InQu®, a differentiated bone graft extender and substitute in  spinal fusion applications that has been used in over 28,000 surgeries at U.S. hospitals to date. 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.